

Memorial Sloan Kettering Cancer Center

Microsatellite instability high (MSI-H): A definitive predictive biomarker for immune checkpoint inhibitors (ICI) yet understudied in underrepresented minorities (URM) with gastrointestinal (GI) cancers

^{1,2}Fiyinfolu Balogun MD, PhD, ¹Catherine O'Connor, ¹Mirella Altoe PhD, ¹Nobel Chowdhury MD, ^{1,3}Debyani Chakravarty PhD, ¹Francisco Sanchez-Vega PhD, ¹Andrea Cercek MD, ¹Michael Foote MD, ⁵Joon Oh Park MD, PhD, ¹Zsofia Stadler, MD, ¹Steven Maron MD, ⁶DaeHee Kim MD, ⁷Dae Won Kim MD, ⁴Choong-kun Lee MD, PhD, ⁸Karyn Ronski MS, ⁸Calvin Chao, MD, ¹Yelena Janjigian MD, ¹Ghassan K. Abou-Alfa MD, MBA, ¹Luis Diaz MD, ^{1,2}Eileen M. O'Reilly MD, ^{1,2}Wungki Park MD MS ¹Memorial Sloan Kettering Cancer Center, New York, NY, ²David M. Rubenstein Center for Pancreatic Cancer Research, ³Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Weill Cornell Medical College, ⁴Yonsei Cancer Center, ⁵Samsung Medical Center, ⁶Brown University, ⁷Moffitt Cancer Center, ⁸Tempus.

Background:

- Mismatch repair deficiency (dMMR) results in MSI-H status and is the first tumor-agnostic biomarker predictive of response to immune checkpoint inhibitors (ICI).
- Among GI cancers, MSI-H is most frequent in colorectal cancer (CRC, 15%) gastroesophageal cancer (GEC, 5%) and small bowel and hepatopancreatobiliary (HPB, <5%).
- For CRC, MSI-H can be attributed to germline mutations (Lynch syndrome, 3%) or somatic inactivation (sporadic, 12%) of foundational MMR genes.
- Studies evaluating ICI efficacy in dMMR cancers focus primarily on non-Hispanic White (NHW) patients (pts).
- In this study, we explore 2 large databases and present data on prevalence, tumor genomic features, and outcomes in underrepresented minority (URM) patients with MSI-H GI cancers

Methods:

Retrospective analysis of MSI-H GI cancers

- Upper: Esophageal + Gastric + GEJ
- Mid: Hepatic + Biliary + Pancreatic + Small bowel
- Lower: Colon + Rectal + Anal

MSK-IMPACT and TEMPUS-LENS databases

Primary analysis performed on MSK-IMPACT and further validation from TEMPUS-LENS

Patients were grouped by self-reported race and ethnicity into 4 arms:

- Non-Hispanic White (NHW)
- Asian
- Non-Hispanic Black (NHB)
- Hispanic
- URM = Asian + NHB + Hispanic


Age at diagnosis, tumor mutation burden (TMB), MMR gene alteration frequency, and molecular ancestry were analyzed using descriptive statistics. Overall survival (OS) was estimated with Kaplan-Meier Methods


Conclusions:

- Proportion of MSI-H GI cancers in URM patients is similar to that seen in NHW pts. However, the number diagnosed were significantly lower by 8 - 15 fold, which indicates significant undertesting in URM patients
- Younger patients were more commonly seen in MSI-H CRC URM compared to NHW.
- Asian and Hispanic patients were 10+ years younger than NHW.
- Overall survival was similar between NHW and URM in patients with unresectable MSI-H colorectal cancer
- based ancestry determination

Results:







Future Directions:

- Comprehensive genomic analysis at MSKCC and TEMPUS database are underway looking at TME and ancestry data.
- Validation of clinicogenomics of MSI-H GI cancers in other large cohorts.
- Determine effect of immunotherapy on survival of NHW and URM patients with MSI-H gastrointestinal cancers.
- Investigate younger age for URM patients with MSI-H GI cancers.

Concordance and similar proportion of MMR gene alteration pattern was seen among self reported races/ethnicities and molecular

Figure 2a. Distribution of MSI-H within GI cancer types in NHW, Hispanic, Black, and Asian HPB – hepatopancreatobiliary, CRC - colorectal




Figure 2b. Frequency of MSI-H in CRC and GEC by race/ethnicity



MSKCC – IMPACT





Table 1. MSI-H frequency, age, TMB, and MMR gene FA by race/ethnicity in MSK-IMPACT and TEMPUS cohorts. MMR gene FA: Most frequently altered MMR gene

_	
-	
 80	
0	

MMR genes MSH6

MLH1 MSH2 PMS2

> MMR genes MSH6 MLH1 MSH2 PMS2



Acknowledgments



- Funding
- NIH K12 Paul Calabresi Award
- NIH P50 Pancreas SPORE (RP2)
- Parker Institute for Cancer Immunotherapy

parkw1@mskcc.org

- The Society of Memorial Sloan Kettering
- Society of Immunotherapy for Cancer
- Break Through Cancer Conquering KRAS in Pancreatic Cancer
- Winn DICT CDA
- Conflict of interest disclosures: Research fund to the Institution: Merck MISP, Astellas, Miracogen, Tempus, BMS

Special thanks: Our patients, friends and family, colleagues, CPCR team







(1)

SOCIETY of MEMORIAL SLOAN KETTERING